A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
Public ClinicalTrials.gov record NCT06679101. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Open-label Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
Study identification
- NCT ID
- NCT06679101
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- GlaxoSmithKline
- Industry
- Enrollment
- 520 participants
Conditions and interventions
Conditions
Interventions
- Belantamab mafodotin Drug
- Daratumumab Drug
- Dexamethasone Drug
- Lenalidomide Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 15, 2024
- Primary completion
- Apr 27, 2031
- Completion
- Apr 27, 2031
- Last update posted
- Apr 21, 2026
2024 – 2031
United States locations
- U.S. sites
- 30
- U.S. states
- 19
- U.S. cities
- 29
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Mobile | Alabama | 36607 | Recruiting |
| GSK Investigational Site | Phoenix | Arizona | 85054 | Recruiting |
| GSK Investigational Site | Beverly Hills | California | 90211 | Recruiting |
| GSK Investigational Site | Pasadena | California | 91105 | Recruiting |
| GSK Investigational Site | Aurora | Colorado | 80012 | Recruiting |
| GSK Investigational Site | Washington D.C. | District of Columbia | 20007 | Recruiting |
| GSK Investigational Site | Englewood | Florida | 34223 | Recruiting |
| GSK Investigational Site | Lady Lake | Florida | 32159 | Recruiting |
| GSK Investigational Site | Pembroke Pines | Florida | 33024 | Recruiting |
| GSK Investigational Site | Saint Augustine | Florida | 32256 | Recruiting |
| GSK Investigational Site | Atlanta | Georgia | 30322 | Recruiting |
| GSK Investigational Site | Portland | Maine | 04074 | Recruiting |
| GSK Investigational Site | Worcester | Massachusetts | 01655 | Recruiting |
| GSK Investigational Site | Ann Arbor | Michigan | 48103 | Recruiting |
| GSK Investigational Site | Detroit | Michigan | 48201 | Recruiting |
| GSK Investigational Site | Billings | Montana | 59102 | Recruiting |
| GSK Investigational Site | Hackensack | New Jersey | 07601 | Recruiting |
| GSK Investigational Site | New York | New York | 10065 | Recruiting |
| GSK Investigational Site | Stony Brook | New York | 11790 | Recruiting |
| GSK Investigational Site | Charlotte | North Carolina | 28204 | Recruiting |
| GSK Investigational Site | Winston-Salem | North Carolina | 27103 | Recruiting |
| GSK Investigational Site | Columbus | Ohio | 43214 | Recruiting |
| GSK Investigational Site | Providence | Rhode Island | 02903 | Recruiting |
| GSK Investigational Site | Austin | Texas | 78705 | Recruiting |
| GSK Investigational Site | Austin | Texas | 78712 | Recruiting |
| GSK Investigational Site | Kingwood | Texas | 77339 | Recruiting |
| GSK Investigational Site | San Antonio | Texas | 78240 | Recruiting |
| GSK Investigational Site | Tyler | Texas | 75702 | Recruiting |
| GSK Investigational Site | Fairfax | Virginia | 22031 | Recruiting |
| GSK Investigational Site | Puyallup | Washington | 98373 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 151 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06679101, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 21, 2026 · Synced May 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06679101 live on ClinicalTrials.gov.